PRESS RELEASE

Q1 2026 — Press release

Q1 2026PDF · 14 pages304 KB
- 1 -
News Release
____________________________________________________________________________
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial
Results; Highlights Significant Regulatory Approvals and Clinical Milestones
Sales Growth Driven by Continued Strength in Oncology and Animal Health, Plus
Increasing Contributions From Launches
- 	Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX)
o 	KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.0 Billion (12% Growth; 8%
Growth ex-FX); Includes KEYTRUDA QLEX Sales of $128 Million
o 	WINREVAIR Sales Were $525 Million (88% Growth; 87% Growth ex-FX)
o 	Animal Health Sales Were $1.8 Billion (13% Growth; 6% Growth ex-FX)
- 	GAAP Loss per Share Was $1.72; Non-GAAP Loss per Share Was $1.28; GAAP and
Non-GAAP Loss per Share Include a Charge of $3.62 per Share for the Acquisition of
Cidara
- 	Presented New Data From Cardio-Pulmonary Pipeline at ACC.26, Including Positive
Results From Phase 3 CORALreef AddOn Trial
- 	Received U.S. FDA Approval for IDVYNSO, a Once-Daily, Oral Treatment for Certain
Adults With Virologically Suppressed HIV-1
- 	Achieved Multiple Significant Regulatory and Clinical Milestones Across Oncology
Pipeline
- 	Announced Agreement To Acquire Terns Pharmaceuticals, Inc. and Expand Hematology
Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia; Transaction
Expected To Close in May
- 	Full-Year 2026 Financial Outlook
o 	Narrows and Raises the Midpoint of Worldwide Sales Range; Now Expects Sales
To Be Between $65.8 Billion and $67.0 Billion
o 	Narrows and Raises Expected Non-GAAP EPS Range To Be Between $5.04
and $5.16
o 	Outlook Does Not Reflect Any Impact From Proposed Acquisition of Terns
Pharmaceuticals, Inc., Which Is Expected To Close in May and Result in a One-
Time Charge of Approximately $5.8 Billion or Approximately $2.35 per Share
RAHWAY, N.J., April 30, 2026 – Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known
as MSD outside the United States and Canada, today announced financial results for the first
quarter of 2026.
1 Available in some markets as KEYTRUDA SC.

-- 1 of 14 --

- 2 -
“We are moving with speed to transform our portfolio to one with a diversified set of
growth drivers across a broad set of therapeutic areas,” said Robert M. Davis, chairman and
chief executive officer. “During the first quarter, we continued to strengthen our pipeline with
science-led business development, including our planned acquisition of Terns. We also
achieved several important milestones, such as the FDA approval of IDVYNSO – which marks a
new chapter in our longstanding commitment to people living with HIV. I am pleased with our
progress and excited for what’s ahead, as we enter a particularly robust period of Phase 3 data
readouts and deliver on the promise of our pipeline for patients.”
Financial Summary
$ in millions, except EPS amounts
First Quarter
2026 	2025 	Change
Change Ex-
Exchange
Sales 	$16,286 	$15,529 	5% 	3%
GAAP net (loss) income2 	(4,240) 	5,079 	N/M 	N/M
Non-GAAP net (loss) income that excludes certain
items 2,3* 	(3,156) 	5,611 	N/M 	N/M
GAAP EPS 	(1.72) 	2.01 	N/M 	N/M
Non-GAAP EPS that excludes certain items 3* 	(1.28) 	2.22 	N/M 	N/M
*Refer to table on page 7.
N/M - Not meaningful.
For the first quarter of 2026, Generally Accepted Accounting Principles (GAAP) loss /
earnings per share (EPS) assuming dilution was a loss per share of $1.72 and non-GAAP loss
per share was $1.28. Both the GAAP and non-GAAP loss per share were due to a charge for
the acquisition of Cidara Therapeutics, Inc. (Cidara) of $3.62 per share.
Non-GAAP EPS excludes acquisition- and divestiture-related costs and costs related to
restructuring programs, as well as income and losses from investments in equity securities.
2 Net (loss) income attributable to the Company.
3 The Company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of
these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP
results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to
measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior
management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in
addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-
GAAP adjustments, see Table 2a attached to this release.

-- 2 of 14 --

- 3 -
First-Quarter Sales Performance
The following table reflects sales of the Company’s top products and significant
performance drivers.
First Quarter
$ in millions 	2026 	2025 	Change
Change Ex-
Exchange 	Commentary
Total Sales 	$16,286 	$15,529 	5% 	3%
Pharmaceutical 	14,349 	13,638 	5% 	2%
Increase primarily driven by growth in
oncology as well as cardiometabolic and
respiratory, partially offset by declines in
vaccines, diabetes and infectious
diseases.
KEYTRUDA/
KEYTRUDA QLEX 	8,034 	7,205 	12% 	8%
Growth primarily driven by higher global
demand in metastatic indications
including urothelial cancer, as well as
strong global uptake in earlier-stage
indications, including triple-negative
breast cancer, cervical cancer and renal
cell carcinoma (RCC). Sales growth
benefited from the timing of wholesaler
purchases in the U.S. Sales of
KEYTRUDA QLEX were $128 million.
GARDASIL/GARDASIL 9 	1,069 	1,327 	-19% 	-22%
Decline primarily due to lower demand in
China as well as lower sales in Japan
following the national catch-up
immunization program. Decline also
reflects lower sales in the U.S. primarily
due to unfavorable public-sector
purchasing patterns, partially offset by
higher net pricing.
JANUVIA/JANUMET 	574 	796 	-28% 	-29%
Decline primarily due to lower demand
and net pricing in the U.S., as well as
lower demand in China and most other
international markets due to generic
competition.
PROQUAD, M-M-R II and
VARIVAX 	538 	539 	0% 	-2%
Sales were flat, primarily driven by
unfavorable private sector purchasing
patterns for M-M-R II and lower demand
for M-M-R II and VARIVAX in the U.S.,
offset by higher PROQUAD sales in the
U.S. due to borrowing of doses in 2025
from a U.S. government stockpile, which
lowered sales in that period.
WINREVAIR 	525 	280 	88% 	87%
Growth primarily reflects continued
uptake in the U.S. and early launch
uptake in certain international markets,
particularly in Japan and Europe.
BRIDION 	472 	441 	7% 	7%
Growth primarily due to higher demand
in the U.S., partially offset by lower
demand in most international markets
due to ongoing generic competition.
Lynparza* 	341 	312 	9% 	6%
Growth primarily due to higher demand
in the U.S. and many international
markets.
PREVYMIS 	272 	208 	31% 	26%
Increase primarily due to higher demand
in the U.S. and certain European
markets, reflecting in part the launch of
new indications.
Lenvima* 	256 	258 	-1% 	-2% 	Relatively flat compared with prior year.

-- 3 of 14 --

- 4 -
First Quarter
$ in millions 	2026 	2025 	Change
Change Ex-
Exchange 	Commentary
ROTATEQ 	206 	228 	-10% 	-11%
Decrease primarily driven by lower
demand in China.
VAXNEUVANCE 	202 	230 	-12% 	-16%
Decrease primarily driven by lower
demand in the U.S. and most
international markets due to competitive
pressure.
WELIREG 	199 	137 	45% 	43%
Growth primarily driven by higher
demand in the U.S. and continued
launch uptake in several international
markets, particularly in Japan and certain
European markets.
CAPVAXIVE 	142 	107 	33% 	31%
Increase primarily driven by launch
uptake in certain European markets and
continued uptake in the U.S. U.S. sales
growth was partially offset by a reduction
in wholesaler inventory.
OHTUVAYRE 	131 	- 	- 	-
Product obtained as part of the
Company’s October 2025 acquisition of
Verona Pharma plc (Verona Pharma).
LAGEVRIO 	28 	102 	-73% 	-73%
Decline largely due to lower demand in
Japan and the U.S.
Animal Health 	1,791 	1,588 	13% 	6%
Growth attributable to performance in
both Livestock and Companion Animal
product portfolios.
Livestock 	1,064 	924 	15% 	8%
Growth primarily driven by higher
demand for ruminant and poultry
products as well as price.
Companion Animal 	727 	664 	9% 	4%
Growth from new product launches and
price was partially offset by lower
demand for other products in portfolio,
reflecting a reduction in veterinary visits.
Sales of BRAVECTO line of products
were $379 million and $327 million in
current and prior-year quarters,
respectively, which represents an
increase of 16%, or 9% excluding impact
of foreign exchange.
Other Revenues** 	146 	303 	-52% 	4%
Decline primarily due to unfavorable
impact of revenue-hedging activities and
lower revenue from third-party
manufacturing arrangements, partially
offset by higher milestones received for
out-licensing arrangements and higher
royalty income.
*Alliance revenue for this product represents the Company’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
In addition, Koselugo alliance revenue was $161 million for the first quarter of 2026 compared
with $44 million for the first quarter of 2025. The increase was due to a $150 million payment received
in the first quarter of 2026 in connection with an amendment to the collaboration agreement with
AstraZeneca in 2025, which (subject to an annual election by AstraZeneca) discontinued the provisions
whereby the Company shared revenue and costs with AstraZeneca, and revised the payment structure.

-- 4 of 14 --

- 5 -
First-Quarter Expense and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs4
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP3
First Quarter 2026
Cost of sales 	$4,195 	$1,014 	$237 	$ - 	$2,944
Selling, general and administrative 	2,700 	32 	- 	- 	2,668
Research and development 	12,592 	- 	34 	- 	12,558
Restructuring costs 	195 	- 	195 	- 	-
Other (income) expense, net 	138 	- 	- 	(180) 	318
First Quarter 2025
Cost of sales 	$3,419 	$620 	$36 	$- 	$2,763
Selling, general and administrative 	2,552 	23 	- 	- 	2,529
Research and development 	3,621 	7 	- 	- 	3,614
Restructuring costs 	69 	- 	69 	- 	-
Other (income) expense, net 	(35) 	(3) 	- 	(107) 	75
GAAP Expense, EPS and Related Information
Gross margin was 74.2% for the first quarter of 2026 compared with 78.0% for the first
quarter of 2025. The decrease was primarily due to higher amortization of intangible assets,
higher restructuring costs, the recognition of inventory fair value step-up related to the 2025
Verona Pharma acquisition and the unfavorable impact of foreign exchange, partially offset by
favorable product mix.
Selling, general and administrative (SG&A) expenses were $2.7 billion in the first quarter
of 2026, an increase of 6% compared with the first quarter of 2025. The increase was primarily
due to higher administrative costs and the unfavorable impact of foreign exchange.
Research and development (R&D) expenses were $12.6 billion in the first quarter of
2026 compared with $3.6 billion in the first quarter of 2025. The increase was primarily due to a
$9.0 billion charge for the acquisition of Cidara, higher clinical development spending, the
unfavorable impact of foreign exchange and restructuring costs, partially offset by a $200 million
reduction in R&D expenses as part of the funding agreement with Blackstone Life Sciences
(Blackstone) and a $100 million charge in the first quarter of 2025 for the achievement of a
developmental milestone related to the 2024 acquisition of EyeBiotech Limited (EyeBio).
Other (income) expense, net, was $138 million of expense in the first quarter of 2026
compared with $35 million of income in the first quarter of 2025. The unfavorability was primarily
due to higher net interest expense, partially offset by higher net income from investments in
equity securities.
4 Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment
charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations, licensing arrangements and asset acquisitions, and recognition of fair
value step-up to inventories for asset acquisitions.

-- 5 of 14 --

- 6 -
The income tax provision for the first quarter of 2026 was $709 million on a pretax loss
of $3.5 billion, resulting in an effective income tax rate of (20.1)%. This effective income tax rate
includes a 33.1 percentage point unfavorable impact of the charge for the acquisition of Cidara,
for which no tax benefit was recorded.
GAAP loss per share was $1.72 for the first quarter of 2026 compared with earnings per
share of $2.01 for the first quarter of 2025, primarily driven by a $3.62 per share charge
included in the first quarter of 2026 for the acquisition of Cidara.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 81.9% for the first quarter of 2026 compared with 82.2%
for the first quarter of 2025. The decrease was primarily due to the unfavorable impact of foreign
exchange, partially offset by favorable product mix.
Non-GAAP SG&A expenses were $2.7 billion in the first quarter of 2026, an increase of
5% compared with the first quarter of 2025. The increase was primarily due to higher
administrative costs and the unfavorable impact of foreign exchange.
Non-GAAP R&D expenses were $12.6 billion in the first quarter of 2026 compared with
$3.6 billion in the first quarter of 2025. The increase was primarily due to a $9.0 billion charge
for the acquisition of Cidara, higher clinical development spending and the unfavorable impact
of foreign exchange, partially offset by a $200 million reduction in R&D expenses as part of the
funding agreement with Blackstone and a $100 million charge in the first quarter of 2025 for the
achievement of a developmental milestone related to the 2024 acquisition of EyeBio.
Non-GAAP other (income) expense, net, was $318 million of expense in the first quarter
of 2026 compared with $75 million of expense in the first quarter of 2025. The unfavorability was
primarily due to higher net interest expense.
The non-GAAP income tax provision for the first quarter of 2026 was $957 million on a
pretax loss of $2.2 billion, resulting in a non-GAAP effective income tax rate of (43.5)%. This
effective income tax rate includes a 57.6 percentage point unfavorable impact of the charge for
the acquisition of Cidara, for which no tax benefit was recorded.
Non-GAAP loss per share was $1.28 for the first quarter of 2026 compared with
earnings per share of $2.22 for the first quarter of 2025, primarily driven by a $3.62 per share
charge included in the first quarter of 2026 for the acquisition of Cidara.

-- 6 of 14 --

- 7 -
A reconciliation of GAAP to non-GAAP net (loss) income and EPS is provided in the
table that follows.
Pipeline and Portfolio Highlights
In the first quarter, the Company continued to advance its pipeline, achieving significant
regulatory and clinical milestones across a broad range of therapeutic areas.
• 	Oncology:
o 	U.S. Food and Drug Administration (FDA) approved KEYTRUDA and
KEYTRUDA QLEX plus paclitaxel, with or without bevacizumab, for the treatment
of certain adults with PD-L1+ (combined positive score [CPS] ≥1) platinum-
resistant ovarian cancer, based on Phase 3 KEYNOTE-B96 trial.
 	The European Commission (EC) also approved this KEYTRUDA regimen
for this population.
o 	In April, FDA approved a label update for KEYTRUDA QLEX based on results
from Phase 2 MK-3475A-F11 trial, which evaluated patient-reported preference
for subcutaneous administration of KEYTRUDA QLEX over intravenous
administration of KEYTRUDA in participants with multiple tumor types.
o 	In April, FDA granted priority review for ifinatamab deruxtecan (I-DXd) for certain
adults with previously treated extensive-stage small cell lung cancer, based on
Phase 2 Ideate-Lung01 trial. I-DXd is part of the Company’s collaboration with
Daiichi Sankyo.
 	FDA set Prescription Drug User Fee Act (PDUFA) date of Oct. 10, 2026.
o 	FDA accepted for priority review supplemental applications for WELIREG in
combination with KEYTRUDA or KEYTRUDA QLEX for the adjuvant treatment of
certain patients with RCC, based on the Phase 3 LITESPARK-022 trial.
 	FDA set PDUFA date of June 19, 2026.
5 Includes the estimated income tax impacts on the reconciling items based on applying the statutory rate of the originating territory
of the non-GAAP adjustments for all periods presented.
First Quarter
$ in millions, except EPS amounts 	2026 	2025
EPS
GAAP EPS 	$(1.72) 	$2.01
Difference 	0.44 	0.21
Non-GAAP EPS that excludes items listed below3 	$(1.28) 	$2.22
Net (Loss) Income
GAAP net (loss) income 2 	$(4,240) 	$5,079
Difference 	1,084 	532
Non-GAAP net (loss) income that excludes items listed below2,3 	$(3,156) 	$5,611
Excluded Items:
Acquisition- and divestiture-related costs 4 	$1,046 	$647
Restructuring costs 	466 	105
Income from investments in equity securities 	(180) 	(107)
Increase to net loss / decrease to net income before taxes 	1,332 	645
Estimated income tax benefit5 	(248) 	(113)
Increase to net loss / decrease to net income 	$1,084 	$532

-- 7 of 14 --

- 8 -
o 	FDA accepted supplemental applications for WELIREG plus Lenvima in certain
previously treated patients with advanced RCC, based on the Phase 3
LITESPARK-011 trial. Lenvima is being developed as part of a collaboration with
Eisai Co., Ltd (Eisai).
 	FDA set PDUFA date of Oct. 4, 2026.
o 	Announced positive results from Phase 3 KEYNOTE-B15 trial (also known as
EV-304) demonstrating KEYTRUDA plus Padcev reduced the risk of event-free
survival (EFS) events by 47% and reduced the risk of death by 35% in cisplatin-
eligible patients with muscle-invasive bladder cancer (MIBC) when given before
and after surgery.
 	KEYNOTE-B15 is the sixth study demonstrating overall survival (OS) with
a KEYTRUDA-based regimen in an earlier-stage cancer.
o 	In April, FDA granted priority review for KEYTRUDA and KEYTRUDA QLEX,
each with Padcev, for cisplatin-eligible patients with MIBC, based on the Phase 3
KEYNOTE-B15 trial.
 	FDA set PDUFA date of Aug. 17, 2026.
o 	In a pre-specified interim analysis of the Phase 3 LITESPARK-012 study,
compared to KEYTRUDA plus Lenvima, the triplet combination therapy of
KEYTRUDA plus Lenvima plus WELIREG, as well as the combination of MK-
1308A (an investigational fixed dose coformulation of KEYTRUDA and the anti-
CTLA-4 antibody quavonlimab) plus Lenvima, did not show a statistically
significant improvement in the primary endpoints of progression-free survival and
OS in patients with advanced clear cell RCC.
o 	In the Phase 3 KEYNOTE-975 study, compared to placebo plus definitive
chemoradiotherapy (dCRT), KEYTRUDA plus dCRT did not show a statistically
significant improvement in the primary endpoint of EFS in certain patients with
locally advanced unresectable esophageal carcinoma.
o 	In a prespecified interim analysis of the Phase 3 KEYNOTE-866 study, compared
to perioperative placebo plus neoadjuvant chemotherapy, perioperative
KEYTRUDA plus neoadjuvant chemotherapy did not show a statistically
significant improvement in the primary endpoint of EFS in patients with cisplatin-
eligible MIBC who underwent radical cystectomy and pelvic lymph node
dissection.
• 	Vaccines and Infectious Diseases:
o 	In April, FDA approved once-daily IDVYNSO, an oral, two-drug, single-tablet
regimen of doravirine/islatravir (DOR/ISL) for the treatment of certain adults with
virologically suppressed HIV-1, based on Phase 3 MK-8591A-051 and MK-
8591A-052 trials. IDVYNSO was also approved in Japan for these patients in
March.
o 	Presented data from three Phase 3 trials evaluating DOR/ISL at the 33rd
Conference on Retroviruses and Opportunistic Infections (CROI), including:
 	Results from Phase 3 MK-8591A-053 trial demonstrated that DOR/ISL is
the first two-drug regimen that does not include an integrase strand

-- 8 of 14 --

- 9 -
transfer inhibitor to demonstrate non-inferiority and similar safety profile at
Week 48 versus bictegravir/emtricitabine/tenofovir alafenamide6 [(50
mg/200 mg/25 mg) (BIC/FTC/TAF)] in adults living with HIV-1 who had
not previously received antiretroviral treatment.
 	Results from the Phase 3 MK-8591A-052 and MK-8591A-051 trials
demonstrated that DOR/ISL maintained virologic suppression at Week 96
in adults with virologically suppressed HIV-1 who switched from other
antiretroviral therapies, including BIC/FTC/TAF.
o 	In April, EC approved ENFLONSIA for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in newborns and infants during their
first RSV season, based on Phase 2b/3 CLEVER and Phase 3 SMART trials.
o 	Announced positive second RSV season results from Phase 3 SMART trial
evaluating the safety, efficacy and pharmacokinetics of ENFLONSIA in infants
and children at increased risk for severe RSV disease over two RSV seasons.
o 	European Medicines Agency’s Committee for Medicinal Products for Human Use
(CHMP) adopted positive opinion for an expanded indication for CAPVAXIVE for
active immunization against invasive pneumococcal disease and
pneumococcal pneumonia in certain children and adolescents at increased risk
of pneumococcal disease.
• 	Cardiometabolic and Respiratory:
o 	Presented new data at the American College of Cardiology’s Annual Scientific
Session and Expo (ACC.26) including:
 	Positive results from Phase 3 CORALreef AddOn trial demonstrated
significantly greater LDL-C reductions at eight weeks compared to
guideline-recommended oral non-statin therapies when added to
background statins. This is the third positive Phase 3 study of enlicitide.
 	Positive data from Phase 2 CADENCE trial provided definitive proof-of-
concept for WINREVAIR in adults with the syndrome of combined post-
and precapillary pulmonary hypertension and heart failure with preserved
ejection fraction (CpcPH-HFpEF). Totality of evidence supports
advancing development of WINREVAIR for this distinct patient population
into a registrational Phase 3 study.
• 	Animal Health:
o 	FDA approved NUMELVI for dogs, the first and only second-generation Janus
kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic
dermatitis in dogs 6 months of age and older.
• 	Business Development:
o 	Announced an agreement to acquire Terns Pharmaceuticals, Inc. (Terns)
through a subsidiary.
6 Bictegravir/emtricitabine/tenofovir alafenamide (BIKTARVY) is a registered trademark of Gilead Sciences, Inc.

-- 9 of 14 --

- 10 -
 	Expands hematology pipeline with the addition of TERN-701, an
investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor
currently in Phase 1/2 development for certain patients with chronic
myeloid leukemia (CML).
 	Transaction expected to close in May.
Notable recent news releases on the Company’s pipeline and portfolio are provided in
the table that follows. Visit the News Releases section of the Company’s website to read the
releases.*
Oncology
KEYTRUDA and KEYTRUDA QLEX, Plus Paclitaxel ± Bevacizumab, FDA Approved for
Certain Adults With PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second-
or Third-Line Treatment; Based on Results From Phase 3 KEYNOTE-B96 Trial
EC Approved KEYTRUDA Plus Paclitaxel ± Bevacizumab for Treatment of Adults With PD-
L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One
or Two Prior Systemic Treatment Regimens; Based on Results From Phase 3 KEYNOTE-
B96 Trial
I-DXd Granted Priority Review in U.S. for Adult Patients With Previously Treated
Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression on or
After Platinum-Based Chemotherapy; Based on Results From Phase 2 Ideate-Lung01
Trial; FDA Set PDUFA Date of Oct. 10, 2026
FDA Granted Priority Review for KEYTRUDA and KEYTRUDA QLEX, Each With Padcev,
for Cisplatin-Eligible Patients With MIBC; Based on Results From Phase 3 KEYNOTE-B15
Trial; FDA Set PDUFA Date of Aug. 17, 2026
KEYTRUDA Plus Padcev Reduced Risk of EFS Events by 47% and Risk of Death by 35%
for Cisplatin-Eligible Patients With MIBC When Given Before and After Surgery; Results
From Phase 3 KEYNOTE-B15 Trial
KEYTRUDA Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key
Secondary Endpoint of OS Versus Paclitaxel With or Without Bevacizumab in Patients
With Platinum-Resistant Recurrent Ovarian Cancer; Results From Phase 3 KEYNOTE-
B96 Trial
KEYTRUDA Plus WELIREG Given as Adjuvant Therapy Reduced Risk of Disease
Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients
With Earlier-Stage RCC; Results From Phase 3 LITESPARK-022 Trial; FDA Set PDUFA
Date of June 19, 2026 for WELIREG in combination with KEYTRUDA or KEYTRUDA
QLEX
WELIREG Plus Lenvima Reduced the Risk of Disease Progression or Death by 30%
Compared to Cabozantinib in Certain Previously Treated Patients With RCC; Results
From Phase 3 LITESPARK-011 Trial; FDA Set PDUFA Date of Oct. 4, 2026
The Company and Eisai Provided Update on Phase 3 LITESPARK-012 Trial Evaluating
First-Line Combination Treatments for Certain Patients With Advanced RCC
Vaccines and
Infectious Diseases
FDA Approved the Company’s Once-Daily IDVYNSO for Adults With Virologically
Suppressed HIV-1; Based on Results From Phase 3 MK-8591A-051 and MK-8591A-052
Trials
The Company Announced Late-Breaking Data From Three Phase 3 Trials Evaluating
DOR/ISL, an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults
Living With HIV-1, at CROI 2026
EC Approved ENFLONSIA for the Prevention of RSV Lower Respiratory Tract Disease in
Infants During Their First RSV Season; Based on Results From Phase 2b/3 CLEVER and
Phase 3 SMART Trials
The Company Announced Positive New Data for ENFLONSIA for Infants and Children
Under 2 Years of Age at Increased Risk for Severe RSV Disease Over Two RSV Seasons;
Results From Phase 3 SMART Trial
The Company Presented New Data Reinforcing Long-Term Efficacy of GARDASIL 9 and
GARDASIL at the EUROGIN International Multidisciplinary HPV Congress 2026

-- 10 of 14 --

- 11 -
Cardiometabolic and
Respiratory
Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly
Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral
Non-Statin Therapies When Added to Background Statins; Results From Phase 3
CORALreef AddOn Trial
Positive Data From Phase 2 CADENCE Trial Provided Definitive Proof-of-Concept for
WINREVAIR in Adults With the Syndrome of CpcPH-HFpEF
Ophthalmology
The Company Initiated Pivotal Phase 2b/3 Trial Evaluating MK-8748, an Investigational
Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related
Macular Degeneration
Animal Health FDA Approved NUMELVI for Dogs – First and Only Second-Generation JAK Inhibitor for
the Control of Pruritus Associated With Allergic Dermatitis
Research
The Company and Mayo Clinic Announced New Research and Development
Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
The Company and Google Cloud Partnered To Accelerate Agentic AI Enterprise
Transformation
*References to the Company’s name in the above news release titles have been modified for the purpose of this announcement.
Upcoming Investor Event
The Company will hold an Oncology Investor Event to coincide with the 2026 American
Society of Clinical Oncology Annual Meeting on Monday, June 1, 2026, 6 p.m. CT, during which
senior management will provide an update on the Company’s oncology strategy and program.
The event will take place in Chicago and will be accessible via live audio webcast at
this weblink.
Full-Year 2026 Financial Outlook
The following table summarizes the Company’s full-year financial outlook.
Full Year 2026
Updated 	Prior
Sales * 	$65.8 billion to $67.0 billion 	$65.5 billion to $67.0 billion
Non-GAAP Gross margin3 	Approximately 82% 	Approximately 82%
Non-GAAP Operating expenses 3** 	$36.0 billion to $36.8 billion 	$35.9 billion to $36.9 billion
Non-GAAP Other (income) expense, net 3 	Approximately $1.3 billion expense 	Approximately $1.3 billion expense
Non-GAAP Effective income tax rate3 	23.5% to 24.5% 	23.5% to 24.5%
Non-GAAP EPS3*** 	$5.04 to $5.16 	$5.00 to $5.15
Share count (assuming dilution) 	Approximately 2.48 billion 	Approximately 2.48 billion
*The Company does not have any non-GAAP adjustments to sales.
**Includes a one-time charge of $9.0 billion for the acquisition of Cidara. Outlook does not reflect the proposed acquisition of Terns or
assume any additional significant potential business development transactions.
***Includes a one-time charge of $3.62 per share for the acquisition of Cidara.
The Company has not provided a reconciliation of forward-looking non-GAAP gross
margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP
effective income tax rate and non-GAAP EPS to the most directly comparable GAAP measures,
given it cannot predict with reasonable certainty the amounts necessary for such a
reconciliation, including intangible asset impairment charges, legal settlements, and income and
losses from investments in equity securities either owned directly or through ownership interests
in investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the Company’s future GAAP results.

-- 11 of 14 --

- 12 -
The Company now anticipates full-year 2026 sales to be between $65.8 billion and
$67.0 billion, including a positive impact from foreign exchange of approximately 1% at mid-April
2026 exchange rates.
The Company continues to expect the full-year non-GAAP effective income tax rate to
be between 23.5% and 24.5% including the impact of the non-tax-deductible one-time charge
for the acquisition of Cidara.
The Company now expects full-year 2026 non-GAAP EPS to be between $5.04 and
$5.16, including a positive impact from foreign exchange of approximately $0.10 per share at
mid-April 2026 exchange rates. This range includes a one-time charge of $9.0 billion, or $3.62
per share, related to the acquisition of Cidara. In 2025, non-GAAP EPS of $8.98 was negatively
impacted by one-time charges of $0.20 per share in the aggregate related to certain business
development transactions.
In April 2026, the Company announced a tender offer to acquire Terns. The Company’s
financial outlook does not reflect this transaction, which is expected to be accounted for as an
asset acquisition and result in a one-time charge of approximately $5.8 billion, or approximately
$2.35 per share. In addition, taking into consideration operational investment to advance TERN-
701, as well as the cost of financing the transaction, the Company also anticipates EPS will be
negatively impacted by approximately $0.12 over the remainder of 2026 following the close,
which is expected in May.
The financial outlook does not assume additional significant potential business
development transactions.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the call
on Thursday, April 30, at 9 a.m. ET via this weblink. A replay of the webcast, along with the
sales and earnings news release, supplemental financial disclosures and slides highlighting the
results, will be available on the Company’s website.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free)
or (517) 308-9448 and using the access code 9818590.
About Our Company
At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States
and Canada, we are unified around our purpose: We use the power of leading-edge science to
save and improve lives around the world. For more than 130 years, we have brought hope to
humanity through the development of important medicines and vaccines. We aspire to be the
premier research-intensive biopharmaceutical company in the world – and today, we are at the
forefront of research to deliver innovative health solutions that advance the prevention and
treatment of diseases in people and animals. We foster a diverse and inclusive global workforce

-- 12 of 14 --

- 13 -
and operate responsibly every day to enable a safe, sustainable and healthy future for all
people and communities.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “Company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the Company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the Company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
Company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise. Additional factors
that could cause results to differ materially from those described in the forward-looking
statements can be found in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2025 and the Company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
ENFLONSIA (clesrovimab-cfor)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
IDVYNSO (doravirine/islatravir)
JANUMET (sitagliptin and metformin HCl)

-- 13 of 14 --

- 14 -
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
OHTUVAYRE (ensifentrine)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
VARIVAX (Varicella Virus Vaccine Live)
ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
NUMELVI (atinvicitinib tablets)
###
Media Contacts: 	Investor Contacts:
Michael Levey
michael.levey@msd.com
John Cummins
john.cummins2@msd.com
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583

-- 14 of 14 --